Spikevax bivalent Original/Omicron BA.4-5 is indicated as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.

A Conditional Marketing Authorisation (CMA) has been granted in the UK for Spikevax bivalent Original/Omicron as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.

Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.

Spikevax bivalent Original/Omicron BA.4-5 is indicated for active immunizsation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.

Spikevax bivalent Original/Omicron BA.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against COVID-19.

Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store and include the vaccine brand and batch/Lot number if available. They can also be reported to Moderna using the Adverse Event Intake Portal or by calling 0800 085 7562.

To report a product quality complaint or for general medical information inquiries, please contact Moderna on 0800 085 7562 or at EMEAMedinfo@modernatx.com